

## ASCO Annual Meeting 2017 Presscast June 3 Part 2

This presscast below has been produced by ASCO. According to the ASCO press release the following studies have been presented in the Saturday June 3 “News of the Day” Part 2 Briefing:

- **The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers** (Abstract [LBA2501](#)) (presscast presentation starts at min 30:30) *The authors conclude that Larotrectinib has demonstrated consistent and durable antitumor activity in TRK fusion cancers, across a wide range of ages and tumor types, and was well-tolerated. Larotrectinib could be the first targeted therapy developed in a tissue type-agnostic manner, and the first developed simultaneously in adults and pediatrics. Read the [full release](#).*
- **Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer** (Abstract [LBA11516](#)) (presscast presentation starts at min 42:24) *The authors conclude that This novel, high-intensity ctDNA assay enabled broad detection of genomic variants in plasma at high rates of concordance with corresponding tumor tissue, providing strong evidence for tumor-derivation of these signals. This study will inform development of a high-intensity sequencing approach for early cancer detection. . Read the [full release](#).*
- **Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the Profiler Study** (Abstract [LBA100](#)) (presscast presentation starts at min 54:30) *The authors conclude that In this series of 2490 cancer pts, CGH and NGS identified actionable alterations on 51% of pts, with treatment recommendation in 35%. Most patients treated derived benefit from the recommended MTT, but these represent a minority of the whole population screened . Read the [full release](#).*